Freiwan A, Zoine JT, Crawford JC, et al. Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies. Blood. 2022;140(25):2684-2696.
Papadimitriou Theodoros Ioannis, Singh Prashant, et al.CD7 activation regulates cytotoxicity-driven pathology in systemic sclerosis, yielding a target for selective cell depletion. Ann Rheum Dis. 2024;83(4):488-498.
Tingting Yang, et al. Interim Phase 1 study of sequential CD7 CAR T-cell therapy and haploidentical HSCT without GVHD prophylaxis in patients with Relapsed/Refractory CD7-positive hematologic malignancies. Blood. 2025;146(1):1040.
Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today. 1994 Sep;15(9):450-4.